466 related articles for article (PubMed ID: 25455847)
1. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.
Raad II; Zakhem AE; Helou GE; Jiang Y; Kontoyiannis DP; Hachem R
Int J Antimicrob Agents; 2015 Mar; 45(3):283-8. PubMed ID: 25455847
[TBL] [Abstract][Full Text] [Related]
2. A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections.
Yilmaz D; Balkan C; Ay Y; Akin M; Karapinar B; Kavakli K
Mycoses; 2011 May; 54(3):234-42. PubMed ID: 19906090
[TBL] [Abstract][Full Text] [Related]
3. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B
J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811
[TBL] [Abstract][Full Text] [Related]
5. Combination antifungal therapy for invasive aspergillosis.
Marr KA; Boeckh M; Carter RA; Kim HW; Corey L
Clin Infect Dis; 2004 Sep; 39(6):797-802. PubMed ID: 15472810
[TBL] [Abstract][Full Text] [Related]
6. Combination antifungal therapy for invasive aspergillosis: a randomized trial.
Marr KA; Schlamm HT; Herbrecht R; Rottinghaus ST; Bow EJ; Cornely OA; Heinz WJ; Jagannatha S; Koh LP; Kontoyiannis DP; Lee DG; Nucci M; Pappas PG; Slavin MA; Queiroz-Telles F; Selleslag D; Walsh TJ; Wingard JR; Maertens JA
Ann Intern Med; 2015 Jan; 162(2):81-9. PubMed ID: 25599346
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of combination antifungal therapy in Korean haematological patients with invasive aspergillosis.
Lee DG; Lee HJ; Yan JL; Lin SS; Aram JA
Mycoses; 2019 Oct; 62(10):969-978. PubMed ID: 31355956
[TBL] [Abstract][Full Text] [Related]
8. Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: efficacy and concomitant cyclosporin A.
Morrissey CO; Slavin MA; O'Reilly MA; Daffy JR; Seymour JF; Schwarer AP; Szer J
Mycoses; 2007; 50 Suppl 1():24-37. PubMed ID: 17394607
[TBL] [Abstract][Full Text] [Related]
9. Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study.
Candoni A; Caira M; Cesaro S; Busca A; Giacchino M; Fanci R; Delia M; Nosari A; Bonini A; Cattaneo C; Melillo L; Caramatti C; Milone G; Scime' R; Picardi M; Fanin R; Pagano L;
Mycoses; 2014 Jun; 57(6):342-50. PubMed ID: 24373120
[TBL] [Abstract][Full Text] [Related]
10. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis.
Maertens J; Glasmacher A; Herbrecht R; Thiebaut A; Cordonnier C; Segal BH; Killar J; Taylor A; Kartsonis N; Patterson TF; Aoun M; Caillot D; Sable C;
Cancer; 2006 Dec; 107(12):2888-97. PubMed ID: 17103444
[TBL] [Abstract][Full Text] [Related]
11. Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registry.
Maertens J; Egerer G; Shin WS; Reichert D; Stek M; Chandwani S; Shivaprakash M; Viscoli C;
BMC Infect Dis; 2010 Jun; 10():182. PubMed ID: 20569436
[TBL] [Abstract][Full Text] [Related]
12. Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients.
Lellek H; Waldenmaier D; Dahlke J; Ayuk FA; Wolschke C; Kröger N; Zander AR
Mycoses; 2011 Jan; 54 Suppl 1():39-44. PubMed ID: 21126271
[TBL] [Abstract][Full Text] [Related]
13. Retrospective evaluation of caspofungin therapy in invasive aspergillosis (RECAM-IA).
Wisniewski T; Klimko N; Laverdiere M; Kiertiburanakul S; Kliasova G; Trenschel R; Kumar RN
Mycoses; 2011 Jul; 54(4):e148-53. PubMed ID: 20202110
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort.
Hiemenz JW; Raad II; Maertens JA; Hachem RY; Saah AJ; Sable CA; Chodakewitz JA; Severino ME; Saddier P; Berman RS; Ryan DM; Dinubile MJ; Patterson TF; Denning DW; Walsh TJ
Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1387-94. PubMed ID: 20703506
[TBL] [Abstract][Full Text] [Related]
15. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study.
Singh N; Limaye AP; Forrest G; Safdar N; Muñoz P; Pursell K; Houston S; Rosso F; Montoya JG; Patton P; Del Busto R; Aguado JM; Fisher RA; Klintmalm GB; Miller R; Wagener MM; Lewis RE; Kontoyiannis DP; Husain S
Transplantation; 2006 Feb; 81(3):320-6. PubMed ID: 16477215
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies.
Kontoyiannis DP; Hachem R; Lewis RE; Rivero GA; Torres HA; Thornby J; Champlin R; Kantarjian H; Bodey GP; Raad II
Cancer; 2003 Jul; 98(2):292-9. PubMed ID: 12872348
[TBL] [Abstract][Full Text] [Related]
17. Treating invasive aspergillosis in patients with hematologic malignancy: diagnostic-driven approach versus empiric therapies.
Dib RW; Hachem RY; Chaftari AM; Ghaly F; Jiang Y; Raad I
BMC Infect Dis; 2018 Dec; 18(1):656. PubMed ID: 30545320
[TBL] [Abstract][Full Text] [Related]
18. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients.
Viscoli C; Herbrecht R; Akan H; Baila L; Sonet A; Gallamini A; Giagounidis A; Marchetti O; Martino R; Meert L; Paesmans M; Ameye L; Shivaprakash M; Ullmann AJ; Maertens J;
J Antimicrob Chemother; 2009 Dec; 64(6):1274-81. PubMed ID: 19841031
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.
Maertens J; Raad I; Petrikkos G; Boogaerts M; Selleslag D; Petersen FB; Sable CA; Kartsonis NA; Ngai A; Taylor A; Patterson TF; Denning DW; Walsh TJ;
Clin Infect Dis; 2004 Dec; 39(11):1563-71. PubMed ID: 15578352
[TBL] [Abstract][Full Text] [Related]
20. Clinical evidence for caspofungin monotherapy in the first-line and salvage therapy of invasive Aspergillus infections.
Heinz WJ; Buchheidt D; Ullmann AJ
Mycoses; 2016 Aug; 59(8):480-93. PubMed ID: 27324802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
